ACIP Recommends JYNNEOS Vaccine for Adults at Risk During Mpox Outbreaks

This is a 2023 recommendation report from the Advisory Committee on Immunization Practices (ACIP). It addresses the use of the JYNNEOS (Smallpox and Mpox Vaccine, Live, Nonreplicating) vaccine for persons aged 18 years and older who are at risk for mpox during an mpox outbreak in the United States. The report describes the committee's recommendation but does not present new study results, primary outcomes, or a comparator group.

No specific efficacy or effectiveness data, such as vaccine efficacy estimates or case reduction numbers, are reported in this summary. The sample size, follow-up duration, and details of the population's specific risk factors are not provided.

Information on safety, tolerability, and adverse events is not reported. The report does not list specific limitations of the evidence considered by ACIP. As a formal recommendation, its practice relevance is to inform clinicians of the updated ACIP guidance for outbreak settings. Providers should consult the complete published recommendations for detailed indications, dosing schedules, and contraindications.